Skip to main
AOD-9604 Store

A plain-spoken research digest of AOD-9604 — the growth-hormone fat-loss fragment, read straight from the trials, including the human one that came up empty.

When a claim sounds too certain

AOD-9604 references behind each finding

Each source number leads to a paper, its year, and a public link.

How does each paper help you judge a claim?

Each small number beside a claim leads to one paper below. The paper names the test group and the result.

Results in animals stay separate from results in people. When you weigh a claim, the adult finding matters most.

Study amounts, lengths, and head counts appear with their paper. The public link opens the full paper or public record.

Some papers use hard lab terms. The plain note says whether people, animals, or cells were tested.

That difference helps you judge the claim. A mouse result cannot answer what happened to an adult.

  1. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. ↗
  2. Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449. ↗
  3. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. ↗
  4. Bornstein J, Ng FM, Heng D, Wong KP. Metabolic actions of pituitary growth hormone. I. Inhibition of acetyl CoA carboxylase by human growth hormone and a carboxyl terminal part sequence acting through a second messenger. Acta Endocrinol (Copenh). 1983;103(4):479-486. ↗
  5. Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab. 2013;3(1-2):7-15. ↗
  6. More MI, Kenley D. Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health. J Endocrinol Metab. 2014;4(3):64-77. ↗
  7. Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015;45(4):426-432. ↗
  8. Adan RA. Central and peripheral molecular targets for antiobesity pharmacotherapy. Clin Pharmacol Ther. 2010;87(6):748-751. ↗
  9. AOD-9604 (Metabolic Pharmaceuticals). Curr Opin Investig Drugs. 2004;5(4):437-441. ↗
  10. Halford JC. Obesity drugs in clinical development. Curr Opin Investig Drugs. 2006;7(4):312-318. ↗
  11. Jensen MD. Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors. Obesity (Silver Spring). 2006;14 Suppl 3:143S-149S. ↗
  12. Khan A, Raza S, Khan Y, Aksoy T, Khan M, Weinberger Y, Goldman J. Current updates in the medical management of obesity. Recent Pat Endocr Metab Immune Drug Discov. 2012;6:117-128. ↗
  13. World Anti-Doping Agency. Prohibited List — Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. WADA; 2024. ↗